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Abstract 
Background: Recently, the role of IL‑19, IL‑20 and IL‑24 has been reported in renal disorders. However, still little is 
known about their biological role.
Methods: Localization of IL‑20RB was determined in human biopsies and in the kidneys of mice that underwent 
unilateral ureteral obstruction (UUO). Renal Il19, Il20 and Il24 expression was determined in ischemia/reperfusion, 
lipopolysaccharide, streptozotocin, or UUO induced animal models of kidney diseases. The effects of  H2O2, LPS, 
TGF‑β1, PDGF‑B and IL‑1β on IL19, IL20 and IL24 expression was determined in peripheral blood mononuclear cells 
(PBMCs). The extents of extracellular matrix (ECM) and α‑SMA, Tgfb1, Pdgfb, and Ctgf expression were determined in 
the kidneys of Il20rb knockout (KO) and wild type (WT) mice following UUO. The effect of IL‑24 was also examined on 
HK‑2 tubular epithelial cells and NRK49F renal fibroblasts.
Results: IL‑20RB was present in the renal biopsies of patients with lupus nephritis, IgA and diabetic nephropathy. 
Amount of IL‑20RB increased in the kidneys of mice underwent UUO. The expression of Il19, Il20 and Il24 increased 
in the animal models of various kidney diseases. IL‑1β,  H2O2 and LPS induced the IL19, IL20 and IL24 expression of 
PBMCs. The extent of ECM, α‑SMA, fibronectin, Tgfb1, Pdgfb, and Ctgf expression was lower in the kidney of Il20rb KO 
compared to WT mice following UUO. IL‑24 treatment induced the apoptosis and TGF‑β1, PDGF‑B, CTGF expression of 
HK‑2 cells.
Conclusions: Our data confirmed the significance of IL‑19, IL‑20 and IL‑24 in the pathomechanism of renal diseases. 
Furthermore, we were the first to demonstrate the pro‑fibrotic effect of IL‑24.
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Background
The prevalence of chronic kidney disease (CKD) is esti-
mated to be 8–16% worldwide, and is rapidly increasing 
[1]. The key risk factors of CKD are the chronic civiliza-
tion diseases including hypertension, diabetes mellitus 
and autoimmune diseases, but acute kidney injury can 
also lead to long-term renal damage [2]. Despite the 
growing medical importance, the pathomechanism of 
CKD is still not fully understood. However, regardless of 
its etiology, the pathomechanism of CKD always has an 
inflammatory component, which leads to the overpro-
duction of pro-fibrotic factors, including transforming 
growth factor (TGF)–β1, platelet-derived growth factor 
(PDGF)-B or connective tissue growth factor (CTGF) 
[3]. These factors are implicated in the activation and 
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proliferation of α smooth muscle actin (α-SMA) positive 
myofibroblasts (MFs), which are the main effector cells 
responsible for the excessive production of extracellular 
matrix (ECM) leading to the destruction of normal kid-
ney architecture, and finally to end-stage renal diseases 
[4].
The IL-20 subfamily of cytokines is part of the IL-10 
family and comprises five related molecules, including 
IL-19, IL-20, IL-22, IL-24, and IL-26. The IL-20 subfam-
ily of cytokines are mainly produced by immune cells 
and have been suggested to enhance tissue repair pro-
cesses [5]. Within the subfamily, IL-19, IL-20, and IL-24 
form a distinct group as they share the common IL-
20RA/IL-20RB and IL-22RA/IL-20RB receptor heter-
odimers [6]. However, the distribution of these receptors 
can vary between tissues, their expression is restricted 
to the epithelial cells in most organs [5]. Recently, con-
nection between IL-20 subfamily of cytokines and CKD 
has been proposed. Indeed, increased serum level of 
IL-19 and IL-24 was demonstrated in diabetic nephrop-
athy and lupus nephritis [7, 8]. Furthermore, our previ-
ous genome-wide analysis performed on new-born rat 
kidneys suggested the possible role of IL-24 in the renal 
tissue remodeling, as well [9]. Although all these data 
indicate a role of the IL-20 subfamily in CKD, little is 
known about the underlying mechanisms. Therefore, in 
our study, we investigated the role of IL-19, IL-20, and 
IL-24 in the pathomechanism of CKD. We examined the 
renal presence of IL-19, IL-20, and IL-24, and their recep-
tors in animal models of different kidney diseases and in 
renal biopsies of patients with different renal diseases. 
Experiments were performed to study the regulation of 
synthesis of IL-19, IL-20 and IL-24. Moreover, the role 
of investigated cytokines in CKD were examined using 
Il20rb KO mice and HK-2 tubular epithelial cells.
Methods
Human kidney biopsies
Human renal biopsy samples were obtained from 
patients with clinically diagnosed diabetic nephropa-
thy, lupus nephritis, and IgA nephropathy. Histologi-
cally intact tumor-free kidney tissues of a patient with 
renal cancer were used as control (n =  1 in all group). 
For more detailed description see Additional file  1: 
Table  S2. All human samples were analyzed in a retro-
spective, anonymized manner, after having received the 
approval of the Semmelweis University Regional and 
Institutional Committee of Science and Research Ethics 
(31224-5/2017/EKU).
Animals and ethic statement
All animal procedures were approved by the Commit-
tee on the Care and Use of Laboratory Animals of the 
Council on Animal Care at Semmelweis University, 
Budapest, Hungary (PEI/001/1731-8/2015). In the exper-
iments 6–8  weeks old male C57BL/6J wild type (WT) 
and Il20rb gene knockout (KO) mice (C57BL/6J back-
ground) [10], obtained from Franz Oswald, University 
Medical Center, Ulm, Germany) or 6–8 weeks old male 
Wistar rats were used. All animals were kept in plastic 
cages under 12 h dark/light cycle at constant temperature 
(24 ±  0.2  °C) with  free access to standard rodent chow 
and drinking water. All surgical procedures were per-
formed under total anesthesia by the intraperitoneal (IP) 
injection of a mixture of 100 mg/kg ketamine and 10 mg/
kg xylazine. After the termination of each experiment, 
kidney and serum samples were collected for the further 
measurements. The serum creatinine and BUN levels 
were determined by standard methods using commer-
cially available kits on a Hitachi 912 chemistry analyzer 
(Roche Hitachi). In UUO experiments, kidney segments 
were fixed in 4% buffered formaldehyde.
Unilateral ureteral obstruction induced nephropathy
Unilateral ureteral obstruction (UUO) or sham surgery 
was performed on WT and Il20rb KO mice, as we previ-
ously described [9]. Briefly, the left ureter of the mice was 
isolated by blunt dissection and completely ligated using 
fine suture material in the UUO group. The sham-oper-
ated (control) animals underwent identical surgical pro-
cedures without the occlusion of the left ureter (n = 6–7 
in each group). Seven (UUO day 7) or 14 days (UUO day 
14) after the initiation of UUO, the left kidneys were sur-
gically removed.
Renal ischemia reperfusion induced acute kidney injury
Renal ischemia/reperfusion (I/R) injury induced acute 
kidney injury was performed on Wistar rats, as we pre-
viously described [11]. Briefly, the left renal pedicle was 
isolated and occluded with an atraumatic microvascular 
clamp for 45 min. Before the end of the ischaemic period, 
the right kidney was removed and the abdomen was 
closed. The sham-operated (control) animals underwent 
identical surgical procedure without clamping the left 
renal artery and vein (n = 5–6 in each group). The rats 
were sacrificed after 24 h of reperfusion.
Streptozotocin‑induced diabetic nephropathy
Streptozotocin (STZ)-induced diabetes was induced in 
Wistar rats as previously described [12]. Briefly, the rats 
received a single IP injection of 65 mg/kg STZ, dissolved 
in 0.1  M citrate buffer (pH 4.5). Control rats received 
equivalent volumes of vehicle without STZ (n = 6 in each 
group). Blood glucose levels were measured three times 
from the tail vein after an overnight fast. Animals were 
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considered diabetic if their peripheral blood glucose level 
was above 15  mmol/l  72  h after the STZ injection and 
remained elevated. The rats were sacrificed 6 weeks after 
STZ injection.
Endotoxin‑induced acute kidney injury
Lipopolysaccharides (LPS)-induced acute kidney injury 
was performed on C57BL/6J mice by a single IP injec-
tion of 10 mg/kg LPS (Escherichia coli serotype 0111:B4; 
Sigma Aldrich). Control mice were IP injected with the 
equal volume of vehicle (n  =  5–6 in each group). The 
mice were sacrificed 24 h after LPS injection.
Recombinant proteins applied for cell culture experiments
Recombinant human interleukin 24 (IL-24), and platelet-
derived growth factor B (PDGF-B) were purchased from 
R&D Systems. Recombinant human interleukin-1 beta 
(IL-1β) and transforming growth factor beta-1 (TGF-β1) 
were purchased from Life Technologies. IL-24 was dis-
solved in sterile phosphate buffered saline (PBS); IL-1β 
was dissolved in sterile distilled water; TGF-β1 and 
PDGF-B were dissolved in HCl (4 mmol/l).
Recombinant proteins
The following recombinant human proteins were used: 
interleukin-24 (IL-24), platelet-derived growth factor B 
(PDGF-B) (R&D Systems) interleukin-1 beta (IL-1β) and 
transforming growth factor beta-1 (TGF-β1) (Life Tech-
nologies). IL-24 was dissolved in sterile phosphate buff-
ered saline (PBS); IL-1β in sterile distilled water; TGF-β1 
and PDGF-B in HCl (4 mmol/l).
Cell culture
Human proximal tubular epithelial cells (HK-2) and nor-
mal rat kidney fibroblast cells (NRK-49F) were purchased 
from American Type Culture Collection (ATCC). Both 
cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (Gibco, Life Technologies) supplemented with 
10% fetal bovine serum (FBS) (Gibco, Life Technolo-
gies) and 1% Penicillin–Streptomycin Solution (Sigma-
Aldrich) in humidified 95% air and 5%  CO2 at 37  °C. 
Before the experiments, the medium was replaced with 
DMEM without FBS for 24  h. For real-time RT-PCR, 
flow cytometric and Western blot analysis HK-2 and 
cells were seeded into 6-well plates at a density of 5 × 105 
cells/well (n  =  5–6 well/treatment group) and treated 
with IL-24 (100 ng/ml) for 24 h.
Peripheral blood mononuclear cells (PBMCs)
PBMCs from adult control and from patients with dia-
betic nephropathy CKD were isolated by density gradient 
centrifugation using Histopaque-1077 (Sigma-Aldrich). 
After isolation, the cells were placed into RPMI 1640 
medium (ATCC) supplemented with 10% FBS and 1% 
Penicillin–Streptomycin Solution in humidified 95% air 
and 5%  CO2 at 37  °C. For real time RT-PCRs, PBMCs 
were seeded into 24 well plates at a density of 5 ×  105 
cells/well (n  =  5–6 well/treatment group) and treated 
either with IL-1β (100 ng/ml), TGF-β1 (5 ng/ml), PDGF-
B (10  ng/ml), LPS (10  ng/ml), or  H2O2 (25  µmol/l) for 
24 h. Vehicle-treated cells served as controls.
MTT cell proliferation and viability assay
For MTT assays, HK-2 and NRK-49F cells were seeded 
into 96-well plates at a density of 4 × 103 cells/well (n = 5 
well/treatment group), and treated with IL-24 (1, 10 
or 100  ng/ml) for 24  h. The assay was performed using 
Cell Proliferation Kit I (Roche Diagnostics) according to 
the manufacturer’s recommendations. Absorbance was 
recorded at 570 nm and at 690 nm as background using 
a Hidex Chameleon Microplate Reader (Triathler, Plate 
Chameleion, 300SL Lablogic Systems) using the Mik-
roWin 2000 software.
LDH cytotoxicity assay
For LDH assays, HK-2 and NRK-49F cells were seeded 
into 96-well plates at a density of 4 × 103 cells/well (n = 5 
well/treatment group) and treated with IL-24 (1, 10 or 
100  ng/ml) for 24  h. LDH assay was performed as pre-
viously described [13]. All reagents were purchased from 
Sigma-Aldrich. Absorbance was recorded at 570 nm and 
at 690 nm as background in a Hidex Chameleon Micro-
plate Reader using the MikroWin 2000 software.
SiriusRed collagen detection assay
For the SiriusRed assay, NRK-49F cells were seeded into 
96-well plates at a density of  104 cells/well (n =  5 well/
treatment group), and treated with IL-24 (100 ng/ml) and 
TGF-β1 (5 ng/ml) for 48 h. The assay was performed as 
previously described [14]. All reagents were purchased 
from Sigma-Aldrich. Absorbance was determined at 
544  nm and at 690  nm as background by Hidex Cha-
meleon Microplate Reader using the MikroWin 2000 
software.
Immunohistochemical analysis
Immunohistochemistry was performed on paraffin-
embedded 5  μm thick tissue sections fixed in forma-
lin (4%, pH 7.4). Slides were deparaffinized in xylene, 
rehydrated in graded ethanol series, and washed in dis-
tilled water. After that, sections were incubated with 
primary IL-20RB specific antibody (ab124332; rabbit, 
1:100, Abcam) for 1  h at room temperature (RT) fol-
lowed by repeated washing in TBS. Secondary antibody 
 [HISTOLS®-R anti-rabbit Detection Systems (Histopa-
thology Ltd.)] was applied for 30 min at RT, followed by 
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repeated washing in TBS. The sections were incubated 
with 3,3ʹ-Diaminobenzidine  (HISTOLS®-DAB chro-
mogen/Substrate System, Histopathology Ltd.), washed 
in distilled water, counterstained with haematoxylin, 
and finally washed in tap water. No first antibody con-
trol was carried out with the omission of primary anti-
body. Sections were then dehydrated, cleared in xylene, 
and mounted with permanent mounting medium (DPX 
Mountant for histology, Sigma-Aldrich). Images were 
taken with a Zeiss AxioImager A1 Light Microscope 
(Carl Zeiss GmbH) using 40× objective from each kidney 
cross-sections with Panoramic Viewer (3DHistech Ltd.).
Immunocytochemistry
HK-2 and NRK-49F cells were seeded in chambers 
(Sarstedt) and cultured for 24 h in 37 °C. After repeated 
washing with PBS, the slides were permeabilized with 
Cytofix/Cytoperm (BD Pharmingen) for 15  min at RT, 
then washed again, and incubated with primary antibody 
specific for IL-20RB (ab124332, rabbit, 1:100, Abcam) 
for 1  h at RT. The slides were then washed with Wash-
Perm solution and incubated with the corresponding 
Alexa Fluor 568 secondary antibody (A10042, anti-rabbit, 
1:200, Invitrogen) for 30  min (min) at RT in darkness 
and counterstained with Hoechst 33342 (1:2000, Sigma-
Aldrich). Finally, slides were coverslipped with Vectash-
ield fluorescent mounting medium (Vector Laboratories). 
Appropriate controls were performed by omitting the 
primary antibodies to assure their specificity and to avoid 
autofluorescence. Slides were analysed with a Nikon C2 
confocal laser scanning microscope system.
Histological analysis
Formalin-fixed paraffin-embedded kidney samples 
were cut into 4-μm sections and stained with Masson’s 
trichome and SiriusRed staining. The sections were 
scanned, and on average 15 non-overlapping areas were 
randomly selected under 200× magnification from each 
kidney section. The analysis of the Masson’s trichrome 
and SiriusRed stained areas was performed with ImageJ 
(The National Institutes of Health). The results were 
expressed as a percentage of the positively stained area of 
Masson’s trichrome and SiriusRed staining.
RNA isolation, reverse transcription and real‑time RT‑PCR
The total RNA was isolated from the kidney samples, 
HK-2, NRK-49F, or PBMC cells by Geneaid Total RNA 
Mini Kit (Geneaid Biotech). RNA was reverse-tran-
scribed using Maxima First Strand cDNA Synthesis 
Kit for RT-qPCR (Life Technologies) to generate first-
stranded cDNA. The mRNA expression of the inves-
tigated genes was determined by real-time PCR using 
LightCycler 480 SYBR Green I Master enzyme mix 
(Roche Diagnostics) on a Light Cycler 480 system (Roche 
Diagnostics). The nucleotide sequences, annealing tem-
peratures of the primer pairs, and the resulting PCR 
product lengths are shown in Additional file 1: Table S1. 
Relative mRNA expressions were determined by com-
parison with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or ribosomal protein lateral stalk subunit P0 
(RPLP0) as internal control using the ∆∆Ct method [15]. 
Data were normalized and presented as the ratio of their 
control values.
Protein isolation and Western blot analysis
Kidney samples or HK-2 cells were homogenized in lysis 
buffer, containing protease inhibitor cocktail (P8340, 
Sigma-Aldrich). The protein concentration of the homog-
enised samples was determined by detergent-compatible 
protein assay (Bio-Rad Laboratories). The samples were 
denatured and separated on 4–20% gradient SDS poly-
acrylamide gel (20  μg protein/lane), then transferred to 
nitrocellulose membranes. The nitrocellulose membranes 
were blocked with 5% non-fat milk in tris-buffered saline 
(TBS) for 1  h at RT. The membranes were incubated 
overnight at 4  °C with antibodies specific for IL-20Rβ 
(ab124332; rabbit, 1:1000, Abcam), fibronectin (ab2413, 
rabbit, 1:1000, Abcam), α-SMA (A2547, mouse, 1:10,000, 
Sigma-Aldrich) or CTGF (sc-14939, goat, 1:1000, Santa 
Cruz Biotechnology) or GAPDH (sc-32233, mouse, 
1:2000, Santa Cruz Biotechnology). After repeated wash-
ing with TBS containing 0.05% Tween-20 and 1% non-fat 
milk, the membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies (sc-2005, 
1:2000 anti-mouse, sc-2020 anti-goat 1:2000, sc-2004, 
anti-rabbit, 1:2000 Santa Cruz Biotechnology) or Alexa 
Fluor 488 secondary antibody (A11001, anti-mouse, 
1:200, Invitrogen) for 1  h at RT. Bands of interest were 
detected using enhanced chemiluminescence detection 
(Luminol Reagent, GE Healthcare) or fluorescence detec-
tion and quantified by densitometry (VersaDoc, Quantity 
One Analysis software; Bio-Rad Laboratories) as inte-
grated optical density after background subtraction. Rel-
ative protein levels were determined by comparison with 
GAPDH as internal control. Data were normalized and 
presented as the ratio of their control values.
Flow cytometry
HK-2 cells were incubated with Fixation/Permeabiliza-
tion solution (BD Bioscience) for 10 min at RT. After per-
meabilization, the cells were washed with Perm/Wash™ 
Buffer (BD Bioscience) and incubated with TGF-β1 (sc-
146, rabbit, 1:50, Santa Cruz Biotechnology) and PDGF-B 
(sc-7878, rabbit, 1:50, Santa Cruz Biotechnology) specific 
antibody for 30  min at RT. The cells were subsequently 
washed with Perm/Wash™ Buffer and incubated with 
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Alexa Fluor 568 secondary antibody (A10042, anti-rabbit, 
1:200, Invitrogen) for 30  min (min) at RT in darkness. 
Appropriate controls were performed omitting the pri-
mary antibodies to assure their specificity and to avoid 
autofluorescence. After that, the cells were washed with 
Perm/Wash™ Buffer and resuspended in PBS. The flow 
cytometric analysis was carried out using a FACSAria 
cytometer (BectonDickinson). The mean fluorescence 
intensity (MFI) values of each sample were normalized 
and presented as the ratio of their control values.
Statistical analysis
The statistical evaluation of data was performed using the 
GraphPad Prism 6.01 software. Mann–Whitney U-test 
was used to determine differences between two groups. 
Multiple comparisons of the data were performed using 
Kruskal–Wallis test with Dunnett correction. p  ≤  0.05 
were considered significant. Values were expressed as 
mean ± SD.
Results
Renal expression of Il19, Il20, Il24 and their receptors 
following UUO
To investigate the expression of Il19, Il20, Il24 and their 
receptors in the kidneys of mice underwent UUO real 
time PCRs were performed. The mRNA expression of 
Il19 was increased on day 14, and Il24 was increased on 
day 7 and day 14  days after the onset of UUO, respec-
tively (Fig.  1a–c). Similarly, the mRNA expression and 
protein level of IL-20RB increased on the 7th and 14th 
day following UUO (Fig. 1f, g). The mRNA expression of 
Il20, Il20ra and Il22ra1 remained unchanged during the 
whole experiment (Fig.  1b, d, e). Moreover, immunhis-
tological staining was performed to determine the renal 
localization of IL-20RB receptor subunit. We observed 
strong IL-20RB immunopositivity in the tubular epithe-
lial and interstitial cells of both sham operated control 
and UUO kidneys (Fig. 1h).
The expression of Il19, Il20 and Il24 in the kidney of I/R‑, 
LPS‑ or STZ‑induced animal models of kidney diseases
To study the role of IL-19, IL-20 and IL-24 in renal 
pathophysiology we investigated their expression in vari-
ous animal models leading to impaired kidney function 
as demonstrated by the increased serum creatinine and 
BUN levels (Additional file  1: Figure S2). The mRNA 
expression of Il19, Il20 and Il24 increased in the kidney of 
rats with I/R-induced acute kidney injury and in the kid-
ney of diabetic rats as well (Fig. 2a, c). While the mRNA 
expression of Il24 increased, the mRNA expression of 
Il19 and Il20 remained unchanged in the kidneys of LPS-
treated mice (Fig. 2b).
Presence of IL‑20RB in human kidney biopsies
In order to demonstrate the presence of IL-20RB in the 
human kidney samples immunohistological stainings 
were performed. We found evident IL-20RB immunopos-
itivity in tubular epithelial and glomerular cells of human 
kidney biopsies obtained from controls and patients with 
diabetic and IgA nephropathy or lupus nephritis (Fig. 3).
Expression of IL19, IL20 and IL24 of PBMCs
To understand the mechanisms leading to increased pro-
duction of IL19, IL20 and IL24 in the injured kidney we 
investigated the effect of several fibrosis related factors 
on their expression in healthy and CKD-derived PBMCs, 
as well. While  H2O2 and LPS treatment increased the 
mRNA expression of IL19, IL20 and IL24, IL-1β treat-
ment increased only that of IL24, TGF-β1 and PDGF-B 
treatment decreased the mRNA expression of IL24 of 
PBMCs derived from healthy adults (Fig. 4a–c). In con-
trast, LPS treatment increased the mRNA expression 
of IL19 and IL24, TGF-β1,  H2O2 and IL-1β treatment 
increased that of IL19, and TGF-β1 treatment decreased 
the mRNA expression of IL20 in CKD-derived PBMCs 
(Fig. 4d–f).
Differences in fibrosis markers in the kidney of WT 
and Il20rb KO mice after UUO
In order to examine the in vivo effect of IL-19, IL-20 and 
IL-24 on renal scarring UUO was performed on Il20rb 
KO and also on WT mice and the renal amount of the 
markers of tissue remodeling were determined. Renal 
amount of α-SMA and fibronectin and also the extent 
of renal Masson’s trichrome and SiriusRed positivity 
increased in both mouse strains, however it remained 
unchanged after 7th day in the Il20rb KO mice, there-
fore, finally, the amount of each fibrosis markers was 
lower in the kidney of the Il20rb KO compared to WT 
mice on day 14 (Fig. 5a–d). The renal mRNA expression 
of pro-fibrotic growth factors including Tgfb1, Pdgfb and 
Ctgf also increased in both strain after UUO. However, 
the expression of these growth factors was lower in the 
kidney of Il20rb KO mice on day 7 following UUO com-
pared to that of WT mice (Fig. 5e–g).
The effects of IL‑24 treatment on the viability 
and pro‑fibrotic growth factor production of HK‑2 cells
Our in  vivo results demonstrated strong IL-20RB 
positivity on kidney tubular epithelial cells. In line 
with this data our immunofluorescence staining 
(Fig. 6a) showed that HK-2 cells also express IL-20RB. 
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Fig. 1 Renal expression of Il19, Il20, Il24 and their receptors following unilateral ureteral obstruction (UUO). Renal mRNA expression of Il19 (a), Il20 
(b), Il24 (c), Il20ra (d), Il20rb (f) and Il22ra1 (e) of mice underwent UUO and that of controls was determined by real‑time RT‑PCR in comparison with 
Gapdh as internal control. The renal protein amount of IL‑20RB of WT mice underwent UUO and that of controls was measured by Western blot 
analysis in comparison with GAPDH as internal control (g and Additional file 1: Figure S4a). Localization of IL‑20RB (brown; h) was investigated by 
immunohistochemical staining in the kidney of mice underwent UUO and in that of controls. Values were expressed as mean ± SD. n = 5–6 in each 
group; *p < 0.05 vs. control (Kruskal–Wallis test). Scale bar: 50 µm (h)
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Furthermore, our results showed that IL-24 treatment 
dose dependently decreased viability of HK-2 cells 
(Fig.  6b). Accordingly, the LDH activity increased in 
the supernatant of IL-24 treated cells (Fig. 6c). Further-
more, IL-24 treatment increased the mRNA expres-
sion of TGFB1, PDGFB and CTGF and protein level of 
TGF-β1, PDGFB and CTGF of HK-2 cells (Fig.  5d–l). 
Interestingly, IL-24 treatment did not modulate the 
viability and ECM production of NRK-49F renal fibro-
blasts (Additional file 1: Figure S1b, d).
Discussion
Previously, our research group identified Il19 and Il24, 
the members of the IL-20 subfamily, as one of the most 
abundantly expressed genes in the kidneys of new-born 
rats that underwent UUO [9]. Within the subfamily, 
IL-19, IL-20, and IL-24 form a distinct group, as they 
Fig. 2 The expression of Il19, Il20 and Il24 in the kidney of ischemia/reperfusion (I/R), lipopolysaccharide (LPS) or streptozotocin (STZ) induced 
animal models of kidney diseases. The renal mRNA expression of Il19, Il20, and Il24 of rats with I/R (a) or LPS (b) induced acute kidney disease, or 
that of STZ‑induced diabetic rats (c) was determined by real‑time RT‑PCR in comparison with Gapdh as internal control. Values were expressed as 
mean ± SD. n = 5–6 in each group; *p < 0.05 vs. control (Mann–Whitney U‑test). Scale bar: 50 µm
Fig. 3 The presence of IL‑20RB in human kidney biopsies. The localization of IL‑20RB was determined by immunohistochemical staining (brown) in 
the kidney biopsy samples obtained from control and patients with diabetic and IgA nephropathy or lupus nephritis. Scale bar: 50 µm
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exert their biological activity by binding to IL-20RA/IL-
20RB or IL-22RA/IL-20RB receptor heterodimers [6].
So far, no differences in the biological activity of 
IL-19, IL-20 and IL-24 have been revealed and also the 
reason of their redundant presence in the kidney is still 
unexplored.
In the present study we demonstrated that IL-20RB 
is abundantly present on the epithelial and glomerular 
cells of patients with CKD of different aetiology, includ-
ing diabetic and IgA nephropathy, or lupus nephritis 
(Fig.  3). Furthermore, we found increased presence 
of IL-20RB on tubular epithelial and glomerular cells 
in the kidneys of mice underwent UUO (Fig.  1g, h). 
IL-20RB is a critical component of the IL-20RA/IL-
20RB or IL-22RA/IL-20RB receptor heterodimers, it 
is responsible not only for ligand binding, but also for 
the formation of the heterodimers, and thus for the 
biological activity of the receptors [16]. Previous stud-
ies found elevated serum level of IL-19 in patients 
with diabetic nephropathy [7]. Moreover, positive cor-
relation was demonstrated between serum IL-24 level 
and the severity of lupus nephritis and renal ischemic/
reperfusion injury [8, 17]. Considering the above data 
strongly implies the role of the IL-20 subfamily in the 
pathomechanism of different renal diseases. Therefore, 
we further investigated the presence, regulation, and 
possible role of the subfamily in the pathomechanism 
of renal diseases.
In line with our previous study on new-born rats, we 
found markedly increased expression of Il19 and Il24 in 
the kidneys of adult mice after the onset of UUO (Fig. 1a–
c). We also demonstrated the increased renal expression 
of Il19, Il20, and Il24 in an I/R-induced rat model of acute 
renal failure (Fig. 2a) and in the STZ-induced rat model of 
diabetic nephropathy, as well (Fig. 2c). However, only the 
renal expression of Il24 increased in the mouse model of 
LPS-induced acute kidney injury (Fig. 2b). These in vivo 
experiments further strengthened the hypothesis about 
the unified importance of the investigated cytokines in 
the different renal pathologies leading to CKD.
Based on the literary data, PBMCs, including lym-
phocytes, monocytes and macrophages, are the poten-
tial source of IL-20 subfamily cytokines in the kidney; 
however, the factors regulating synthesis of IL-19, 
IL-20, and IL-24 in CKD have not been previously 
clarified [18–20]. Therefore, in the present study, we 
investigated the role of those factors, including TGF-
β1, PDGF-B, IL-1β,  H2O2 and LPS, which play a cen-
tral role in the pathomechanism of the different animal 
models of the above mentioned renal diseases (Fig. 4a–
f ) [21, 22]. We found that the effect of oxidative stress 
and LPS treatment was the most pronounced on the 
Fig. 4 The effect of fibrosis related factors on the expression of IL19, IL20, and IL24 in PBMCs. The mRNA expression of IL19, IL20, and IL24 in healthy 
(a–c) and CKD‑derived (d–f) PBMCs after TGF‑β1, PDGF‑B,  H2O2, IL‑1β, and LPS treatment was measured by real‑time RT‑PCR in a comparison with 
RPLP0 as internal control. Values were expressed as mean ± SD. n = 5–6 in each group; *p < 0.05 vs. control (Mann–Whitney U‑test)
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Fig. 5 Alteration of fibrosis markers in the kidneys of WT and Il20rb KO mice following UUO. The blue areas of the Masson’s trichrome and the red 
areas of the SiriusRed‑stained kidney sections represent the collagen deposits of WT and Il20rb KO mice following the onset of UUO (Fig. 3a, b). 
The protein amount of fibronectin and α‑SMA in the kidney tissue of WT and Il20rb KO mice after UUO was measured by Western blot analysis in 
comparison with GAPDH as internal control (c, d and Additional file 1: Figure S4b, c). The renal mRNA expression of Tgfb1 (e) Pdgfb (f) and Ctgf (g) in 
the kidney tissues of WT and Il20rb KO mice was determined by real‑time PCR in comparison with Gapdh as internal control. Values were expressed 
as mean ± SD. n = 6–7 in each group; *p < 0.05 vs. control (Kruskal–Wallis test); #p < 0.05 vs. WT UUO day 7 (Mann–Whitney U‑test); $p < 0.05 vs. WT 
UUO day 14 (Mann–Whitney U‑test). Scale bar: 50 µm (a, b)
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expression of IL19, IL20, and IL24 of PBMCs, origi-
nated from healthy adults. Moreover, in accordance 
with Kunz et al., who demonstrated the IL-1β mediated 
expression of IL19 and IL24 in keratinocytes, we found 
that IL-1β treatment induced the expression of IL19 
and IL24 in PBMCs, as well [23]. On the other hand, we 
Fig. 5 continued
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Fig. 6 Effect of IL‑24 treatment on HK‑2 cells. Presence of IL‑20RB (red) was determined by immunofluorescence staining on HK‑2 cells (a). Cell 
nuclei were counterstained with Hoechst 33342 (blue). Cell viability was determined by MTT (b) and LDH (c) assays. The mRNA expression of TGFB1 
(d) PDGFB (g) CTGF (j) after IL‑24 treatment (100 ng/ml) was measured by real‑time RT‑PCR in comparison with GAPDH as internal control. The 
protein level of TGF‑β1 (e, f) PDGF‑B (h, i) after IL‑24 treatment (100 ng/ml) was measured by flow cytometry (g, h). The protein level of CTGF (k, 
l) after IL‑24 treatment (100 ng/ml) was measured by Western blot analysis in comparison with GAPDH as internal control (l and Additional file 1: 
Figure S4d.) Values were expressed as mean ± SD. n = 5–6 in each group; *p < 0.05 vs. control (Mann–Whitney U‑test). Scale bar: 50 µm (a)
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found that core factors of tissue remodelling, including 
TGF-β1 and PDGF-B decreased the IL24 expression 
of healthy PBMCs. Interestingly, the regulation of the 
investigated cytokines showed different pattern in the 
PBMCs of patients with diabetic nephropathy. While 
the expression of IL19 was increased by several factor 
including TGF-β1, IL-1β, LPS and  H2O2, the expres-
sion of IL20 or IL24 remained mainly unchanged, 
only LPS treatment induced the expression of IL24. 
The response of PBMCs of different origin to TGF-β1 
treatment is of particular interest. While TGF-β1 or 
PDGF-B treatment decreased the expression of IL24 
of healthy PBMCs, TGF-β1 increased the synthesis 
of IL19 in the PBMCs of CKD patients. Previously, in 
accordance with our present results we demonstrated 
that TGFβ treatment decrease the IL-24 expression of 
PBMCs derived from children with coeliac disease [24]. 
Speculating about the possible molecular mechanism 
previously, it has been shown that TGF-β1 may induce 
the expression of IL-1 receptor-associated kinase M 
(IRAK-M), which is a well-known inhibitor of cytokine 
expression [25]. Moreover, Gorelik et  al. found that 
TGF-β inhibit the expression of cytokines through the 
inhibition of GATA binding protein 3 (GATA3) expres-
sion, which is known to be involved in the regulation 
of IL-24 expression of the Th2 lymphocytes [26–28]. 
Taken together our results demonstrate that PBMCs 
are capable to produce the cytokines of the IL-20 sub-
family in response to the prominent mediators of renal 
diseases, however there is a clear difference between 
the PBMCs of healthy adults and those of patients with 
CKD, which may be due to the previous activation of 
the PBMCs originating from patients with CKD [29]. 
In the next set of experiments, the effects of the inves-
tigated cytokines were further studied in mice lacking 
IL-20RB. We found that the protein level of α-SMA, 
which is a marker of the myofibroblasts (MFs), is lower 
in the kidneys of Il20rb KO mice underwent UUO com-
pared to that of WT ones (Fig. 5d). MFs are responsible 
for the production of collagens and fibronectin, which 
are the most common components of the scar tissue 
[30]. Accordingly, we found less increased ECM depo-
sitions, and fibronectin level in  kidneys of Il20rb KO 
than in those of WT mice underwent UUO (Fig. 5a–c), 
which implies the pro-fibrotic role of the investigated 
cytokines. Our results are in line with the previous 
observations implying the role IL-19 in intestinal and 
the role of IL-24 in liver fibrosis and wound healing [19, 
31, 32]. Moreover, our results are in accordance with 
Van belle et al. who found that the genetic deficiency of 
Il20rb resulted in less severe contact dermatitis, which 
is also characterized by increased collagen depositions 
[33].
Investigating the underlying molecular mechanisms, 
we found a decreased expression of Tgfb1,  Pdgfb  and 
Ctgf, the core factors of renal fibrosis in the kidneys of 
Il20rb KO compared to WT mice after UUO (Fig. 5e–
g). All these growth factors play a well-known role in 
the regulation of tissue remodelling [34]. TGF-β1 and 
CTGF promote MF differentiation and induce the 
excessive production of ECM components, includ-
ing collagens and fibronectin. Similarly, PDGF-B is a 
mitogenic growth factor inducing the proliferation of 
MFs [35]. Therefore, it is easy to accept that decreased 
deposition of ECM is closely related to the decreased 
amount of the investigated growth factors in Il20rb KO 
compared to WT mice.
Since IL-20RB is markedly present on the renal tubu-
lar epithelial cells of different human biopsies and also 
on that of mice that underwent UUO, further in  vitro 
experiments were performed on HK-2 tubular epithe-
lial cells expressing IL-20RB (Fig.  6a). In these experi-
ments, we focused on the effects of IL-24, the renal 
expression of which increased to the greatest extent in 
our in  vivo experiments. Indeed, we found that IL-24 
treatment induced the death of HK-2 cells in a dose-
dependent manner (Fig. 6b, c). Previously, the apopto-
sis-inducing ability of IL-24 was thought to be specific 
to cancer cells only, however, in line with our present 
experiment, Hsu and Li et al., demonstrated that mem-
bers of the subfamily including IL-19 and IL-20 induce 
apoptosis of HK-2 kidney epithelial and M1 cortical 
duct cells [36–38].
Moreover, in line with our in vivo experiments dem-
onstrating that the lack of IL-20RB is associated with 
decreased synthesis of Tgfb1, Pdgfb and Ctgf, we found 
that IL-24 treatment induces TGF-β1, PDGF-B  and 
CTGF synthesis of HK-2 tubular epithelial cells in vitro 
(Fig. 6d–l). Interestingly, IL-24 treatment had no effect 
either on the proliferation, or on the ECM production 
of NRK-49F renal fibroblasts (Additional file  1: Figure 
S1b, d). Therefore, we imply that IL-24 may act indi-
rectly on renal myofibroblasts via an increased epithe-
lial production of the pro-fibrotic growth factors. This 
hypothesis is also supported by the observation that 
the extent of the scar tissue was smaller in the kidney 
of Il20rb KO mice underwent UUO compared to that 
of WT mice. However, since IL-19 and IL-20 signal 
through the same receptor complexes it is also possible 
that they exert similar effects on the scar tissue forma-
tion, therefore further experiments are needed to clar-
ify their role in the process of renal fibrosis.
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Conclusions
In summary, we showed the presence of IL-20RB in 
the kidneys of experimental animals, and also in kid-
ney biopsy specimens of patients with diabetic and IgA 
nephropathy, or lupus nephritis. We also demonstrated 
the increased production of Il19, Il20, and Il24 in the kid-
ney samples from the different animal models of acute 
and chronic kidney disease. Furthermore, we defined a 
role of IL-20RB on the renal fibrosis in  vivo. Moreover, 
our experiments described the role of IL-1β, TGF-β1, 
PDGF-B, LPS, and oxidative stress on the synthesis of 
IL-19, IL-20 and IL-24 of PBMCs. Finally, we have also 
shown the effect of IL-24 on the viability and TGF-β1, 
PDGF-B, and CTGF production of the renal tubular 
Fig. 7 Schematic representation of how the IL‑20 cytokine subfamily members may mediate the progression of tissue fibrosis. Our results 
demonstrated the increased expression of Il19, Il20, and Il24 in different renal pathologies. We have shown the role of IL‑1β, TGF‑β, PDGF‑B,  H2O2, 
LPS on the regulation of Il19, Il20, and Il24 expression of the PBMCs. We also demonstrated the presence of their common receptor subunit, IL‑20RB 
on kidney epithelial cells. Moreover, we described the role of IL‑20RB in the renal fibrosis. Furthermore, we revealed the effect of IL‑24 on profibrotic 
growth factor production of renal tubular epithelial cells that may lead to activation of renal myofibroblasts
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epithelial cells in  vitro and in  vivo. Our observations 
raise the possibility that the increased renal production 
of IL-24 may activate the IL-20RB-associated signaling 
pathways leading to increased epithelial cell death and 
an improved synthesis of pro-fibrotic factors (Fig.  7). 
We hope that our work may contribute to the better 
understanding of the pathomechanism of CKD, and 
to the development of new diagnostic and therapeutic 
approaches to treat CKD.
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